Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain the clinical and preclinical effects of pridopidine. This study therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Geva, Michal, Kusko, Rebecca, Soares, Holly, Fowler, Kevin D., Birnberg, Tal, Barash, Steve, -Wagner, Avia Merenlender, Fine, Tania, Lysaght, Andrew, Weiner, Brian, Cha, Yoonjeong, Kolitz, Sarah, Towfic, Fadi, Orbach, Aric, Laufer, Ralph, Zeskind, Ben, Grossman, Iris, Hayden, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291233/
https://www.ncbi.nlm.nih.gov/pubmed/27466197
http://dx.doi.org/10.1093/hmg/ddw238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291233/
https://www.ncbi.nlm.nih.gov/pubmed/27466197
http://dx.doi.org/10.1093/hmg/ddw238

Ejemplares similares